Trial Profile
Safety and efficacy outcome in surgical patients with end stage renal disease recieving sugammadex as a reversal agent: A quality improvement study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 30 Nov 2018
Price :
$35
*
At a glance
- Drugs Sugammadex (Primary)
- Indications Neuromuscular blockade
- Focus Adverse reactions; Therapeutic Use
- 30 Nov 2018 New trial record
- 17 Oct 2018 Results presented at the ANESTHESIOLOGY 2018: Annual Meeting of the American Society of Anesthesiologists